TherapeuticsMD Announces FDA Approval Of IMVEXXY — For Real This Time

TherapeuticsMD Inc TXMD popped as much as 7 percent Wednesday after the company announced that the U.S. Food and Drug Administration approved its TX-004HR: IMVEXXY for moderate to severe dyspareunia, or painful sexual intercourse. 

Why It’s Important

Last week, TherapeuticsMD soared when a prematurely published marketing website for Imvexxy falsely touted the therapy as approved and prepped for sale.

The company removed the website as soon as the market reacted, blamed the false news on media and confirmed that the FDA hadn’t yet ruled on the drug.

Now, TherapeuticsMD has republished the same Imvexxy website and assured that the product is, in fact, approved.

Investors responded to the confirmation as eagerly as they did last week. The stock traded up 4.2 percent by the time of publication.

What’s Next

Imvexxy will be available for purchase in July at a price comparable with that of existing therapies.

Related Links:

TherapeuticsMD Up 40% After Mixed Q3, Plans To Resubmit NDA For TX-004HR

FDA Expresses Concern On TherapeuticsMD; Oppenheimer Downgrades

Photo courtesy of TherapeuticsMD.